Aug 2026· Neurobiology of Disease· Vol 229, pp.
107573
· 0 citations· 114 references
Medicine
Abstract
First-line stimulant therapies for attention deficit hyperactivity disorder (ADHD) implicate the forebrain monoaminergic neurotransmitter systems of dopamine, noradrenaline and serotonin. However, there is no curative treatment. Investigation of neurochemical monoaminergic changes, followed by curative treatments, requires sub-type specific animal models. In a novel rat model of the hyperactive-impulsive and attentive subtype of ADHD, specific changes in forebrain monoamines, and correlations with ADHD-like hyperactivity/impulsivity after delayed reward, are unknown. To address this, we investigated the monoaminergic systems using high performance liquid chromatography at ~2 and 7 months-of-age. We correlated the latter findings with ADHD-like hyperactivity and impulsivity that was measured after delayed reward. We observed long-term effects on the serotonergic, dopaminergic and noradrenergic systems in the forebrain of ADHD-like, hyperactive-impulsive male rats exposed to repeated hypoxia during postnatal day 1-3, the equivalent of extreme prematurity. These long-term effects were strikingly correlated with ADHD-like impulsive, and mostly with ADHD-like hyperactive, behaviour after delayed reward. The correlation was stronger for the dopaminergic and noradrenergic systems and weaker for the serotonergic system. The findings strongly implicate the dopaminergic system in the right prefrontal cortex, the noradrenergic system in the left prefrontal cortex and the serotonergic system in the right posterior caudate-putamen in ADHD-like hyperactivity and ADHD-like impulsivity. Earlier reports of forebrain lateralisation and lifespan changes of monoamines and their metabolites, and of marked differences between the anterior versus posterior caudate-putamen bilaterally, were confirmed and extended. New treatments to collectively cure the neurochemical changes can now be investigated in this unique, ADHD-like subtype-specific animal model.
Methylphenidate (MPH) is a widely used pharmacological treatment for attention deficit/hyperactivity disorder (ADHD), which increases the extracellular dopamine and noradrenaline level by inhibiting their reuptake. Despite reported improvements in cognitive functions, the influence of medication history on MPH efficacy...
M. Shimizu, Ryuta Aoki, T. Itahashi et al.· Asian Journal of Psychiatry· 0 citations
The findings did not establish that psychomotor or vegetative symptoms were associated with GABA levels or GABAA-receptor availability in the frontostriatal pathways or hypothalamus, and future studies should ideally focus on patients exhibiting more pronounced psychomotor and vegetative symptoms and examine additional...
Linda Steinholtz, Jonas Persson, E. Thörnblom et al.· BMC Psychiatry· 1 citation
It is suggested that cuprizone-induced intoxication disrupts VTA-mPFC circuitry, leading to mesocortical dopamine hypofunction, altered cortical plasticity, and executive dysfunction, and support targeting mesocortical dopamine transmission as a potential strategy for MS-related cognitive symptoms.
Laura Dazzi, G. Talani, F. Biggio et al.· Neurobiology of Disease· 0 citations
Abstract Background Rodent models of schizophrenia suggest that combined dopaminergic, glutamatergic and GABAergic neurotransmitter disturbances play a key role in the illness pathophysiology, but whether this translates to patient samples is unknown. Furthermore, non-dopaminergic neurotransmitter disturbances may be m...
K. Bojesen, C. Lemvigh, E. Rostrup et al.· International Journal of Neu...· 0 citations
A comprehensive overview of current pharmacological strategies in severe TR-OCD is provided, highlighting glutamatergic modulation — notably memantine — while integrating serotonergic, dopaminergic, and other emerging therapies, to offer hope for patients unresponsive to conventional pharmacotherapy.
B. Fernández, R. Diós, J. Justo· International Journal of Neu...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.